Doseology Sciences Inc. specializes in the cultivation and extraction of nutraceutical and pharmaceutical products, focusing on medicinal mushrooms. Key strengths include a high gross margin of 70.3% and strong liquidity, indicated by a current ratio of 13.51. However, the company faces significant concerns with extremely negative EBITDA and net margins, suggesting operational inefficiencies. The stark contrast between high margins and low valuation, alongside a market cap of only $801.16K, raises questions about sustainability and growth potential. Overall, while liquidity is strong, profitability remains a critical issue.
Loading financial metrics...
Revenue fell 50.9% year-over-year from $67K to $33K. The decline has persisted for multiple quarters.
Gross profit margin declined from 75.0% to 46.6% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-547K over the last year, representing 1663.6% of revenue.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Excellent liquidity with current ratio of 13.5x ensures operational stability.
Low debt-to-revenue ratio of 0.0% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q1 (September 30, 2025)